Party Drug Ketamine (Special K) Likely To Become Anti-Depression Medicine
The drug Ketamine, known in the party scene as "Special K," could have a future in depression treatment. Pharmaceutical companies are racing to create a patentable version of the drug and researchers are trying to learn more about the effects it has on the brain. Ketamine works by blocking the signalling molecule NMDA, which is a component of the glutamate pathway. This pathway is involved with memory and cognition, psychiatrist James Murrough at the Mount Sinai Hospital in New York City, explained to Nature magazine.
- Dr. James Murrough, Assistant Professor, Psychiatry, Neuroscience, Icahn School of Medicine at Mount Sinai

Mount Sinai Surgeons Perform First Heart-Liver-Kidney Transplants in New York State
May 20, 2025 View All Press Releases
Mount Sinai Study Advances Understanding of Personalized Vaccines for Bladder Cancer
May 12, 2025 View All Press Releases
Mechanism by Which the Brain Weighs Positive vs. Negative Social Experience Is Revealed
Apr 30, 2025 View All Press Releases